NAD+ Peptides vs NAD+ Precursors: A Research Comparison for Australian Researchers

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell, essential for redox reactions in glycolysis, the TCA cycle, and oxidative phosphorylation. Beyond its metabolic role, NAD+ serves as a substrate for several key regulatory enzymes:

• Sirtuins (SIRT1–7), NAD+-dependent deacylases involved in gene expression, DNA repair, and metabolic regulation; central to many longevity research models
• PARPs (poly-ADP-ribose polymerases), consume NAD+ during DNA damage repair; PARP activation after genotoxic stress can transiently deplete cellular NAD+
• CD38, an NAD+ hydrolase whose expression increases with age, contributing to the age-related decline in NAD+ levels observed in multiple tissues

Cellular NAD+ levels decline significantly with age, studies in rodents and humans report reductions of 40–60% in various tissues by middle age. This decline is hypothesised to contribute to reduced sirtuin activity, impaired DNA repair, mitochondrial dysfunction, and metabolic dysregulation.

Direct NAD+ administration bypasses the biosynthetic pathway and delivers the coenzyme directly. In research models, intravenous or intraperitoneal NAD+ administration produces rapid increases in tissue NAD+ levels.

A key limitation of oral NAD+ is its relatively poor bioavailability, NAD+ is a charged molecule that does not readily cross cell membranes intact, and is partially degraded in the gut before absorption. Research using injectable or IV NAD+ avoids this limitation and has formed the basis of several clinical investigations into NAD+ repletion in ageing and metabolic disease models.

Given the bioavailability challenge with direct NAD+ administration, researchers have investigated precursor molecules that enter cells more readily and are converted to NAD+ intracellularly:

• NMN (nicotinamide mononucleotide), a direct NAD+ precursor; enters cells via the Slc12a8 transporter and is converted to NAD+ by NMNAT enzymes. Extensively studied by David Sinclair's group and others; shown to increase NAD+ levels in multiple mouse tissues and reverse several age-related phenotypes in rodent models
• NR (nicotinamide riboside), a precursor that enters cells as NR and is phosphorylated to NMN before conversion to NAD+. Multiple human clinical trials have demonstrated NR supplementation raises blood NAD+ metabolite levels; effects on downstream sirtuin activity are more variable

The relative merit of NMN vs NR remains an active area of research. Both produce measurable increases in NAD+ metabolites, but tissue distribution, conversion efficiency, and downstream effects appear to differ between compounds and between tissues.

For researchers designing experiments around NAD+ biology, the choice between direct NAD+ and precursors involves several considerations:

• Speed of effect, direct IV/IP NAD+ produces the fastest tissue-level increase; oral precursors require time for absorption and enzymatic conversion
• Tissue targeting, NMN and NR show different tissue distribution profiles; muscle, liver, and brain may respond differently to each precursor
• PARP competition, in models with high DNA damage burden, PARP activation competes with sirtuins for NAD+; precursor supplementation may be insufficient to overcome this competition
• Cost and practicality, NAD+ precursors are generally more cost-effective for chronic dosing models; direct NAD+ is preferred in acute depletion or IV-administration research designs

OzPeps supplies research-grade NAD+ Australia-wide. View current NAD+ stock and pricing →

All NAD+ products supplied by OzPeps are for laboratory and in-vitro research purposes only. They are not TGA-approved therapeutic goods and are not intended for human or animal consumption.